Potential for Larger Gene Panels to Increase the Number of Molecularly Matched Therapies in Patients with Advanced Solid Tumours By Ogkologos - April 22, 2025 739 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ProfiLER-02 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Getting Help for Sexual Health Problems When You Have Head and... April 14, 2022 How to Stay Connected When Your Partner Has Cancer May 11, 2022 ESMO Calls for the European Commission to Propose an EU Directive... October 7, 2026 2-Time Cancer Survivor Warns Against Breast Implants After 4 Doctors Missed... June 25, 2019 Load more HOT NEWS EU Cancer Mission and Partners Launch First Cancer Mission Forum for... Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab... Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours Keeping progress in oncology on the agenda: ESMO honours recipients of...
